Uniquity Bio Inc.

Uniquity Bio is a clinical-stage drug development company focused on immunology and inflammation. It identifies and advances novel therapeutic programs for immune-mediated diseases, aiming to address unmet needs and improve patients’ lives. Its development model combines pharmaceutical-grade scientific rigor with biotech-style operational agility; its lead asset, solrikitug, is a monoclonal antibody targeting TSLP being developed for respiratory and gastrointestinal conditions. The company is backed by Blackstone Life Sciences.